EF Hutton Initiates Coverage On FibroBiologics with Buy Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on FibroBiologics with a Buy rating and set a price target of $16.
September 04, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on FibroBiologics with a Buy rating and a price target of $16, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by EF Hutton suggests a positive sentiment towards FibroBiologics. This can lead to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100